中国临床药理学杂志2018，Vol.34Issue(2)：111-113,3.DOI:10.13699/j.cnki.1001-6821.2018.02.005
康莱特注射液联合吉西他滨注射液和替吉奥胶囊治疗晚期胰腺癌的临床研究
Clinical trial of Kanglaite injection combined with gemcitabine injection and tegafur-gimeracil-oteracil potassium capsule in the treatment of advanced pancreatic cancer
张新峰 1乔翠霞 2程旭锋 3刘琦 3高启龙 1杨旭初 1王怀璋1
作者信息
- 1. 郑州大学附属肿瘤医院中西医科,郑州450008
- 2. 河南省中医药研究院附属医院肿瘤科,郑州450008
- 3. 河南中医药大学科研处,郑州450008
- 折叠
摘要
Abstract
Objective To evaluate the clinical efficacy and safety of Kanglaite injection combined with emcitabine injection and tegafur-gimeracil-oteracil potassium capsule in the treatment of advanced pancreatic cancer(PC).Methods A total of 45 patients with advanced pancreatic cancer were randomly divided into treatment group (n =23) and control group (n =22).The control group was given gemcitabine (1000 mg · m2,iv gtt,at day 1 and day 8) and tegafur-gimeracil-oteracil potassium capsule (1.25 m2 ≤ body surface area ＜ 1.5 m2,40 mg,bid;body surface area≥ 1.5 m2,50 mg,bid,day 1-day 14).The treatment group was treated with Kanglaite (20 g,qd,day 1-day 14) on the basis of control group.Both groups were treated for more than 4 cycles.The clinical benefit rate (CBR),overall survival (OS) and the adverse drug reactions (ADRs) were evaluated between the two groups.Results The CBR of treatment group and control group were 78.26％ (18 cases/23 cases) and 50.00％ (11 cases/22 cases) respectively,with significant difference (P ＜ 0.05).The median OS of treatment group and control group were 6.67 months and 5.60 months,respectively,with significant difference (P ＜ 0.05).The ADRs in the treatment group and control group were bone marrow depression,fatigue,gastrointestinal reaction,abnormal liver and kidney function and skin reaction,and there was no significant difference in the incidence of ADRs reactions between the two groups (P ＞ 0.05).Conclusion Kanglaite combined gemcitabine and tegafur-gimeracil-oteracil potassium is effective and safe in the treatment of advanced pancreatic cancer,with a longer OS,a higher incidence of clinical benefit and less ADRs.关键词
胰腺癌/康莱特注射液/吉西他滨注射液/替吉奥胶囊Key words
pancreatic cancer/Kanglaite injection/gemcitabine injection/tegafur-gimeracil-oteracil potassium capsule分类
医药卫生引用本文复制引用
张新峰,乔翠霞,程旭锋,刘琦,高启龙,杨旭初,王怀璋..康莱特注射液联合吉西他滨注射液和替吉奥胶囊治疗晚期胰腺癌的临床研究[J].中国临床药理学杂志,2018,34(2):111-113,3.
